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Abstract
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is required for EBV immortalization of primary B cells in vitro. Signal transducers and activators of transcription (STATs) play a pivotal role in the initiation and maintenance of certain cancers. STAT proteins, especially STAT-1, -3, and -5, are persistently tyrosine phosphorylated or activated in many cancers. We show here that EBV-infected type III latency cells, in which the EBV oncoprotein, LMP-1 is expressed, express high levels of four STATs (STAT-1, -2, -3, and -5A) and that LMP-1 is
responsible for the induction of three (STAT-1, -2, and -3). In addition, the C-terminal activator region 1 (CTAR-1) and CTAR-2 of LMP-1 cooperatively induced the expression of STAT-1. The cooperativity was evident when CTAR-1 and CTAR-2 were present in cis, but not in trans.
Furthermore, NF-κB is an essential factor involved in the induction of STAT-1. Most of the induced STATs were not phosphorylated at the critical tyrosine residue activated by many cytokines. However, the induced STATs, at least STAT-1, were functional because it could be activated
by interferon (IFN) and could upregulate an IFN-inducible gene. Finally, expression of STAT-1, but not STAT-2 and -3, is associated with EBV
transformation. The association of the expression of STAT-1, -2, -3, and -5A with EBV type III latency and the expression of STAT-1 in the
EBV transformation process may be part of the viral programming that regulates viral latency and cellular transformation.
Keywords: LMP-1, STAT-1, Epstein-Barr virus, latency

Introduction

EBNA1 is the major viral protein synthesized in this form of
latency. Latent membrane protein 2A (LMP2A) may also be
expressed. Type II latency is exemplified by NPC and Hodgkin’s disease. EBNA1, LMP-1, LMP2A, and LMP2B proteins are expressed in type II latency. Type III latency is typical of early phases of EBV lymphoproliferative syndromes
and is captured in lymphoblastoid cell lines (LCLs). Nine viral proteins are expressed, including all six nuclear proteins
(EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and
EBNA-LP) and the three integral membrane proteins (LMP1, LMP-2A, and LMP-2B) (reviewed in Kieff, 1996 and
Rickinson and Kieff, 1996).
EBV immortalizes and transforms B cells from cord and
adult blood into LCLs and concomitantly establishes type
III latency in vitro. LMP-1 expression is required for the im-

Epstein-Barr virus (EBV) is a human herpesvirus of increasing medical importance. EBV infection is associated
with the development of nasopharyngeal carcinoma (NPC)
and Burkitt’s lymphoma (BL). In addition, EBV infection is
an important cause of lymphomas in severely immunocompromised persons, especially patients with AIDS and organtransplant recipients (Kieff, 1996; Pagano, 1991; Pagano,
1999; Raab-Traub, 1996; Rickinson and Kieff, 1996).
The biologic hallmark of the EBV–lymphocyte interaction is latency. Three types of latency have been described,
each having its own distinct pattern of gene expression.
Type I latency is exemplified by BL tumors in vivo and earlier passages of cultured cell lines derived from BL biopsies.
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mortalization process (Kaye et al., 1993; Kilger et al., 1998).
LMP-1 can induce a variety of cellular genes that enhance
cell survival as well as adhesive, invasive, and angiogenic potential (Fries et al., 1996; Henderson et al., 1991; Miller et
al., 1995; Murono et al., 2001; Wakasaka and Pagano, 2003;
Wakasaka et al., 2002; Wakasaka et al., 2004; Wang et al.,
1985; Wang et al., 1990a; Yoshizaki et al., 1998).
LMP-1 is an integral membrane protein with six transmembrane-spanning domains and a C-terminal domain located in
the cytoplasm (Kieff, 1996; Liebowitz et al., 1986). LMP-1
acts as a constitutively active receptor-like molecule that does
not need a ligand (Gires et al., 1997). The transmembrane domains mediate oligomerization of LMP-1 molecules in the
plasma membrane, a prerequisite for LMP-1 function (Floettmann et al., 1996; Gires et al., 1997). Two regions in its C terminus initiate signaling processes, the C-terminal activator region 1 (CTAR-1, amino acids 194–231) and CTAR-2 (amino
acids 332–386) ( Figure 1; Huen et al., 1995; Mitchell and
Sugden, 1995).

Figure 1. Molecular structure and locations of functional domains in LMP-1.
LMP-1 contains a short cytoplasmic amino terminus, a transmembrane hydrophobic domain, and a long cytoplasmic carboxy terminus that contains three
major signaling domains. CTAR-1 mediates interaction with the TRAFs, and
is the minor NF-κB-activating region. The location of the TRAF-interacting
motif, PXQXT, is indicated. CTAR-2 is the major NF-κB-activating region.
Also, CTAR-2 can activate JNK and p38 molecules. Two JAK3-binding sites
are also indicated; the JAK-STAT pathway might be activated by interaction
between JAK3 and LMP-1. The amino acid numbers are shown. The drawing is not on scale.
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CTAR-1 is a contributor to the activation of nuclear factor
κB (NF-κB) by LMP-1. The PXQXT motif localized within
CTAR-1 is involved in the interaction with tumor necrosis factor receptor (TNFR)-associated factors (TRAFs). TRAF-1, -2,
-3, and -5 associate with LMP-1 with different affinities and
are responsible for NF-κB activation by CTAR-1 (Devergne et
al., 1996; Devergne et al., 1998; Miller et al., 1997; Sandberg
et al., 1997). CTAR-1 is responsible for induction of epidermal
growth factor receptor (EGFR) and TRAF-1 (Devergne et al.,
1998; Miller et al., 1997). CTAR-1 is required for the transformation of B cells by EBV, and the PXQXT motif is essential
for this process (Izumi et al., 1997; Kaye et al., 1999).
CTAR-2 is also a contributor to the activation of NF-κB by
LMP-1. CTAR-2, through its interaction with TNFR-associated death domain protein (TRADD), activates NF-κB (Izumi
and Kieff, 1997; Izumi et al., 1999). Also, c-jun N-terminal
kinase (JNK) and p38 are activated by CTAR-2 (Eliopoulos
and Young, 1998; Eliopoulos et al., 1999; Kieser et al., 1997).
The final three amino acids (YYD) play an essential role in
the signal transduction pathways of CTAR-2.
Interestingly, consensus janus kinase 3 (JAK3) binding
sites between CTAR-1 and CTAR-2 have been identified (Figure 1). However, whether JAK3 can bind to these sites and is
responsible for the activation of signal transducer and activator of transcription 1 (STAT-1) or other STATs is controversial
(Brennan et al., 2001; Fielding et al., 2001; Gires et al., 1999;
Higuchi et al., 2002).
STATs are a family of latent transcription factors that become activated by phosphorylation on a single tyrosine, typically in response to extracellular ligands (Darnell et al., 1994;
Stark, 1997). Virtually every cytokine and growth factor can
cause STAT phosphorylation through receptor or associated
kinases. Once phosphorylated, STATs can form homo- or heterodimers that accumulate in the nucleus, recognize specific
DNA sequences, and activate transcription (Darnell et al.,
1994; Stark, 1997).
In this report, the relation between EBV and STATs is examined. We show that high levels of expression of STAT-1,
-2, -3, and -5A are associated with EBV type III latency in
which LMP-1 is expressed. LMP-1 stimulates the expression of STAT-1, -2, and -3, but not STAT-5A. Interestingly, the
maximum induction of STAT-1 is a result of a cooperative interaction between the LMP-1 CTAR-1 and CTAR-2 domains.
However, after induction by LMP-1, STAT-1 is not activated
by phosphorylation. Induction of STATs, especially STAT1, -3, and -5A, by EBV may be relevant to viral transformation processes as well as the pathogenesis of EBV-associated
tumors.
Results
Expression of STAT-1 is correlated with LMP-1 protein in
type III latency
We first scanned the expression pattern of STAT-1 in various EBV-infected cell lines with type I or type III latency
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Figure 2. High expression levels of STAT-1 are associated with the expression of LMP-1. Equal amounts of protein lysates from cell lines were electrophoresed
in 8% SDS-PAGE and stained with Ponceau S Red after transfer of protein to the membrane. Western blotting with STAT-1, LMP-1, and tubulin antibodies was
performed simultaneously. The names of cell lines are as labeled. SAV I and SAV III are genetically identical cell lines derived from the same parental line.

profiles. Sav I and Sav III are sister BL lines each derived
from a single parental cell line. The paired lines differ only
in their types of latency (Nonkwelo et al., 1996; Zhang and
Pagano, 1997). The Jijoye (type III) cell line has all the latency genes in its viral genome, whereas its derivative, the
P3HR1 line, lacks the EBNA-2 gene and a portion of EBNALP (Adldinger et al., 1985). As a result of the deletion,
P3HR1 cells do not express EBNA-2, and consequently because EBNA-2 transactivates the LMP-1 promoter (Abbot et
al., 1990; Ghosh and Kieff, 1990; Tsang et al., 1991; Wang
et al., 1990b), express a very low level of LMP-1 apparently
through induction by IRF-7 (Ning et al., 2003). BL41-P3HR1
and BL41-B95-8 are converted by infection of EBV-negative
BL41 cells with either P3HR1 or B95-8 virus, respectively
(Calender et al., 1987). In addition to these paired cell lines,
other available EBV latently infected cell lines were also examined. As shown in Figure 2, STAT-1 protein was expressed
at high levels in type III cell lines with high levels of LMP-1.
In type I cells in which LMP-1 is not expressed, STAT-1 was
expressed at much lower levels. These data indicate that the
expression of STAT-1 correlated with the expression of LMP1 in type III latency.

Akata cells; however, EBNA-2 seems to have no effect on
the induction of STAT-1 in DG75 cells. Therefore, LMP-1 is
probably responsible for the induction of STAT-1 in type III
latency cells. If EBNA2 is involved in the induction of STATs,
it is likely to do so indirectly via induction of LMP-1 in EBVinfected cells.
LMP-1 induces the expression of STAT-1, STAT-2, and STAT-3
Whether LMP-1 increases STAT-1 at the RNA level was
examined by RNase Protection Assays (RPA) with specific
probes. The probe set is capable of detecting RNA of all
STATs (see “Materials and methods” for details). Pairs of the
genetically identical Sav I and Sav III cell lines, as well as
P3HR1 cells and its parental line, Jijoye, were used for the experiments. As shown in Figure 4, STAT-1 RNA levels were
higher in Sav III and Jijoye lines (lanes 2 and 7). Therefore,

LMP-1 stimulates the expression of STAT-1 protein
Because EBNA-2 is the primary inducer of LMP-1 mRNA
(Abbot et al., 1990; Ghosh and Kieff, 1990; Tsang et al., 1991
and Wang et al., 1990b), and because of the consistent association between STAT-1 and LMP-1 expression (Figure 2), it is
possible that either EBNA-2 and/or LMP-1 are responsible for
the induction of STAT-1. Both EBV-negative DG75 and EBVpositive Akata cells were used to determine which viral gene
could directly induce the expression of STAT-1. LMP-1 or
EBNA-2 and a CD4-expression plasmid were transfected into
cells, and the levels of STAT-1 were determined by Western
blotting after selection of the transfected cells by the use of
CD-4 antibody-conjugated magnetic beads (see Materials and
methods). As shown in Figure 3, LMP-1 expression causes a
marked increase in STAT-1 protein levels in both DG75 and

Figure 3. LMP-1 induces the expression of STAT-1 protein. Lysates from
cells transfected with pcDNA3 (lanes 1 and 3) or LMP-1 expression plasmid
(lanes 2 and 4), or EBNA2 expression plasmid (lane 5) were used. Western
blots with STAT-1, LMP-1, EBNA-2, and tubulin antibodies were performed.
Lanes 1 and 2, Akata cells were used for transfection; lanes 3–5, DG75 cells
used. The identity of proteins is as shown.
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Figure 4. LMP-1 induces the expression of endogenous STAT-1, -2, and -3. (A) LMP-1 induces the expression of endogenous STAT-1, -2, and -3 RNA. Human
STAT RPA probes were labeled with α-32P-UTP and used for RPA. Lane 11, undigested STATs probes; lanes 1, 2, 6, and 7, RNAs from P3HR1, Jijoye, Sav I and
Sav III cells, respectively; lane 8, yeast tRNA; lane 5, blank. Lanes 3, 4, 9, and 10, RNAs from transfected and concentrated Akata cells; lanes 3 and 9, pcDNA3;
lanes 4 and 10, LMP-1 expression plasmid. The identity of the STATs is as indicated. (B) The relative levels of STAT RNAs induced by LMP-1. The autoradiography was examined by the Gene Genius Bioimaging System, and the intensity of bands was recorded and analyzed. The results from three independent experiments (two of which are shown in lanes 3, 4, 9, and 10 in panel A) were used for calculations of the induction. STAT-6 was used as an internal control. The relative levels of STAT-1, -2, -3, and standard deviations are shown. (C) LMP-1 induces the expression of endogenous STAT-2 and -3 proteins. Cell lysates from
transfected and concentrated Akata cells were used for Western blot analysis. The identity of proteins is as shown.

STAT-1 RNA expression is also associated with LMP-1 expression, in agreement with the data in Figure 2. Surprisingly,
in addition to STAT-1, expression levels of STAT-2, -3, and 5A RNAs were also higher in type III latency cells (lanes 1, 2,
6, and 7). STAT-1, -2, -3, and -5A RNAs were also expressed
at higher levels in CBC/B95-8 (an LCL, type III latency, with
high level expression of LMP-1) and lower in Eli-BL (type
I latency, no LMP-1 expression) (data not shown). Thus, the

expression of STAT-2, -3, and -5A RNAs is also associated
with type III latency.
Whether LMP-1 increases STAT RNAs was examined by
transient transfection of LMP-1 and a CD4-expression plasmid into Akata cells and selecting transfected cells as before.
As shown in Figure 4, LMP-1 expression produces increased
levels of STAT-1, -2, and -3 RNAs; duplicate results are
shown in lanes 3 and 4, and lanes 9 and 10. However, LMP-1
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did not increase the expression of STAT-5A RNA (lanes 3, 4,
9, and 10). The relative STAT RNA levels are shown in Figure
4B. In addition, we tested if LMP-1 could induce the expression of STAT-2 and -3 proteins. In Akata cells, both STAT-2
and -3 are induced by the expression of LMP-1 as shown in
Figure 4C. In DG75 cells, STAT-2 protein was also efficiently
induced; however, the induction of STAT-3 protein was not
very obvious (data not shown). The data together indicate that
LMP-1 increases the expression of STAT-1, -2, and -3, but not
STAT-5A.
CTAR-1 and CTAR-2 cooperatively induce the expression of
STAT-1
Next, the LMP-1 domain requirement for the induction
of STAT-1 was examined in Akata cells by the use of several
LMP-1 mutants. Akata cells were used for these experiments
because STAT-1 is highly inducible in this cell line (Figure 3
and Figure 4). We tested the role of CTARs in the induction of
STAT-1 in the context of the whole LMP-1 molecule. LMPPQAA has mutations in CTAR1 PXQXT motif that change the
proline and glutamine into alanines. PQAA mutation in intact
LMP-1 will knock out the function of the TRAF-interaction
domain (Devergne et al., 1998; Miller et al., 1998; Sandberg
et al., 1997). LMP-IID has mutations in the CTAR-2 YYD
motif that change the two tyrosines into isoleucines. The tyrosines (Y) in the last three amino acids of LMP-1 (YYD) have
been shown to play an important role in the signaling pathway of CTAR2; mutations of the tyrosine amino acids abolish TRADD binding and the activation of NF-κB and AP-1 by
the CTAR-2 region (Floettmann and Rowe, 1997; Izumi et al.,
1999; Kieser et al., 1997). LMP-DM has mutations in both
CTARs (Figure 5A). As shown in Figure 5B, LMP-PQAA or
LMP-IID induces very marginal levels of STAT-1. When both
CTARs were mutated in LMP-DM, STAT-1 induction is completely abolished. Because either CTAR alone only marginally
induces STAT-1, these data suggest that CTAR1 and CTAR2
cooperatively induce the expression of STAT-1.
Whether the full induction of STAT-1 can be complemented
in trans was examined by co-transfection of individually mutated CTAR-1 and CTAR-2 mutants. As shown in Figure
5B, co-transfection of LMP-1 plasmids containing individually mutated CTAR-1 (LMP-PQAA) and CTAR-2 (LMP-IID)
barely induces STAT-1 and certainly not at a level comparable
to that induced by LMP-1wt. These data suggest that CTAR1
and CTAR-2 cooperatively induce STAT-1 only in cis configuration, but not in trans.
NF-κB is essential for the induction of STAT-1 by LMP-1
Next, the roles of intracellular molecules involved in the
induction were examined. Both CTARs can activate NF-κB as
shown in Figure 6B. In addition, several other molecules have
been shown to be activated by LMP-1. As shown in Figure 6A,
LMP-1 alone induced high levels of STAT-1 in either Akata or
DG75 cells. However, in the presence of superrepressor IκB

Figure 5. Cooperativity between both CTARs is required for efficient induction of STAT-1. (A) Schematic diagram of LMP-1 and its mutants. Solid
ovals, CTAR1 PXQXT motif; solid bars, CTAR-2 YYD motif. X denotes the
destruction of the motifs. LMP-PQAA has mutations in the conserved PXQXT motif that change the proline and glutamine into alanines. LMP-IID has
mutations in the CTAR-2 YYD motif that change the two tyrosines into isoleucines. LMP-DM has mutations in both CTAR-1 and CTAR-2. (B) Akata
cells were transfected with pcDNA-3 vector or the various LMP-1 plasmids
shown in A. The cell lysates were used for Western blot analysis. The identity
of the proteins is indicated.

(sr-IκB), the expression of STAT-1 was completely abolished.
Surprisingly, dominant-negative mutants for TRAFs (TRAF1, -2, -3, and -5 DNs) were not able to block the induction of
STAT-1 efficiently even though the level of LMP-1 expressed
was similar. In addition, AP-1DN and JAK3DN were not able
to block the induction (data not shown).
Because NF-κB is essential for the induction of STAT-1,
and both CTARs are capable of activating NF-κB, we asked
whether NF-κB activation might be contributing to the cooperative induction of STAT-1 by CTAR-1 and -2. As shown
in Figure 6B, the two CTAR mutations could activate NFκB individually as predicted, and the combination of the two
was able to activate NF-κB to a similar level as wild-type
LMP-1. These data are in contrast to the requirement for the
cis configuration of the CTARs for the induction of STAT-1
and suggest that other factors in addition to NF-κB are also
involved.
Phosphorylation of Tyrosine 701 in STAT-1 is not detected in
EBV latency
STAT-1, -3, and -5 are often activated in human cancers.
Phosphorylation at the critical Tyr-701 residue of STAT-1 is
a crucial event for its function although the role of activated
STAT-1 in oncogenesis is not clear yet. We tested the activation status of STAT-1 by the use of phospho-specific antibod-
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Figure 6. NF-κB is required for the induction of STAT-1. (A) NF-κB is required for the induction of STAT-1. Akata or DG75 cells were transfected with pcDNA3 vector or LMP-1, or LMP-1 plus sr-IκB, or LMP-1 plus a combination of dominant-negative mutants of TRAF-1, -2, -3, and -5 (TRAF DNs). The cell lysates
were used for Western blot analysis. The identity of proteins is as shown. (B) LMP-1 activates NF-κB activity in Akata cells. Akata cells were transfected with
NF-κB-reporter construct along with pcDNA-3 or various LMP-1 expression plasmids. Luciferase activities were normalized by β-galactosidase activity. The reporter activity is expressed relative to vector control. Standard deviations are shown.

ies. As shown in Figure 7A, STAT-1 is not phosphorylated, or
very marginally activated, at the critical Tyr-701 residue in all
the EBV-positive cell lines tested including Akata, Jijoye, and
Sav III (lanes 1 and 3, and data not shown). However, STAT1 in these cells is capable of being phosphorylated in response
to IFN-α, suggesting that the STAT-1 is functional (lanes 2
and 4). We also tested the phosphorylation status of serine
727 (Ser-727). Interestingly, the STAT-1 Ser-727 is apparently
constitutively phosphorylated (lanes 5–8). Because Ser-727 is
also phosphorylated in type I latency cells (data not shown),
the results suggest that the phosphorylation of Ser-727 is independent of LMP-1. In addition, the subcellular localization
of STAT-1 was examined by immunostaining in Jijoye cells,
in which STAT-1 is highly expressed (Figure 2). Without IFN
treatment, STAT-1 predominantly localized in the cytoplasm;
however, STAT-1 was predominantly localized to the nucleus
upon IFN treatment as predicted (data not shown). It is noteworthy that we did not observe any phosphorylation and nuclear translocation of STAT-1 in LMP-1-transfected human B
cells (data not shown).
In addition to phosphorylation of the tyrosine residue, IFN
can induce its target genes. As shown in Figure 7B, interferon-

stimulated gene 15 (ISG-15) could be induced in all four cell
lines tested. All these results suggest that STAT-1 in type III
latency cells is not activated, or very marginally activated, at
the critical tyrosine residue (Tyr-701). However, the induced
STAT-1 is functional and capable of responding to IFN.
We also determined the activation status of STAT-3 and 5, both of which are associated with human cancers. Phospho-STAT-3-specific or phospho-STAT-5-specific antibodies
were used to determine the activation status of STAT-3 and
-5. Neither STAT was phosphorylated, or phosphorylated at
very low levels in type III latency cells. However, STAT-3
and -5 could be activated by IL-6 (for STAT-3) or IL-2 (for
STAT-5) (data not shown). These data on the activation status of STAT-3 and -5 are in agreement with a recent report
(Higuchi et al., 2002).
Expression of STAT-1 is associated with EBV transformation
STATs are involved in the pathogenesis of human cancers.
STATs, especially STAT-1, -3, and -5, are persistently tyrosine phosphorylated or activated and play a pivotal role in
initiation and maintenance of the phenotypes of some cancers
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Figure 7. Activation status of STAT-1 in EBV-infected cells. (A) Phosphorylation status of STAT-1 in type III latent cells. Western blot with phosphospecific STAT-1 antibodies was first performed. The membranes were then
stripped and antibody against intact STAT-1 was used to determine the total STAT-1 expression. Lanes 2, 5, 6, and 8 are lysates of cells that had been
treated with IFN-α for 30 min. Lanes 1, 3, 5, and 7 are untreated lysates. Cell
lines are labeled at the top. (B) ISG-15 is inducible in latent cells. Lysates
from cells treated with IFN-α (12 h) were used. Western blots with ISG-15
and tubulin antibodies were performed. The identity of proteins is as shown.

(for a review, see Bowman et al., 2000; Bromberg and Darnell, 2000).
EBV can immortalize and transform primary B cells into
continually growing lymphoblastoid cell lines (LCLs). We
examined if STATs are associated with this immortalization/
transformation process. The primary B cells were isolated
from fresh blood by CD-19-conjugated magnetic beads (see
“Materials and methods” for details). Primary B cells from
two individuals were compared with four newly transformed
LCLs. As shown in Figure 8, the expression of STAT-1 is associated with the EBV immortalization/transformation process. Interestingly, expression of STAT-2, -3, and -5A is apparently not associated with this process (Figure 8A). Although
we have shown clearly that LMP-1 induces STAT-2 and -3,
CD-19-positive primary B cells are heterogeneous and therefore differ from the clonal type I latency and EBV-negative
Burkitt’s lymphoma cell lines. In addition, it has been documented that at least one LMP-1-induced gene, Bcl-2, is not
associated with EBV transformation (Henderson et al., 1991;
Martin et al., 1993), and we confirmed this observation (Figure 8A). Thus, STAT-1 is the only one identified that is associated with EBV transformation.
Next, we examined if the phosphorylation of STATs is associated with EBV transformation processes. Because of the
availability of phospho-STAT antibodies, the phosphorylation
status of STAT-1, -3, and -5 were examined by Western blot

Figure 8. Expression of STAT-1 is associated with EBV transformation processes. (A) STAT-1 expression is induced during the process of immortalization of B lymphocytes by EBV. Primary B cells were isolated from fresh
blood. Equal amounts of protein lysates from primary B cells and four newly
transformed LCLs were electrophoresed, and Western blotting with various
antibodies was performed. The identity of proteins is indicated. (B) STAT-1 is
not phosphorylated at a critical tyrosine residue during EBV transformation.
Western blot with phospho-specific (Tyr-701) STAT-1 antibodies was first
performed. The membranes were then stripped, and antibodies against total
STAT-1, LMP-1, and tubulin were used to determine expression of these proteins. The positive control is Jijoye cells treated with IFN-α for 30 min. The
identity of proteins is as shown.
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analysis. As shown in Figure 8B, STAT-1 was not phosphorylated at the critical Tyr-701 residue. STAT-3 and -5 were not
activated either (data not shown), in agreement with the recent
report (Higuchi et al., 2002).
Discussion
EBV has the capability of deregulating B-cell growth
through activation of endogenous programs of cellular gene
expression. We show that high levels of STAT-1, -2, -3, and 5A are associated with EBV type III latency cells. In addition,
LMP-1, a key type III latency gene, could induce the expression of STAT-1, -2 and -3; however, it could not induce the
expression of STAT-5A RNA (Figure 4).
Some genes can be induced by both LMP-1 CTARs, especially those that are regulated primarily by NF-κB (Mehl et
al., 2001; Miller et al., 1997; Takeshita et al., 1999). In this
report, we have shown a cooperative induction of STAT-1 by
the two CTARs in the cis configuration (Figure 5B). The requirement for efficient induction of STAT-1 by both CTARs
in cis (Figure 5) is interesting and suggests that LMP-1 in
vivo might assume a functional conformation maintained
by both CTARs. The cooperativity is apparently not due to
the activation of NF-κB because activation of NF-κB by the
CTARs was not cooperative in the same cells (Figure 6B).
However, NF-κB is an essential factor for the induction of
STAT-1 (Figure 6). It is obvious that another factor(s) resulting from the cooperation of the two CTARs is also involved
in the induction of STAT-1. It is somewhat surprising that the
combination of TRAF DNs including TRAF-1,-2, -3, and -5
could not efficiently block the induction of STAT-1 (Figure
6A). Because CTAR-1 is apparently involved in the activation (Figure 5B), the results also suggest that another TRAF
member(s), or signaling pathway(s) derived from the TRAF
binding domain might be responsible for partial induction of
STAT-1.
LMP-1 has been reported to activate STAT-1 protein by
phosphorylation via JAK-3 based mainly on studies carried
out in a fibroblast cell line (Gires et al., 1999). However, we
examined the STAT-1 and LMP-1 in native environments in
B cells and found that STAT-1 was not phosphorylated in any
of the type III cell lines in which both LMP-1 and STAT-1 are
highly expressed. Also, we did not observe any phosphorylation and nuclear translocation of STAT-1 by transfecting LMP1 into human B cells (data not shown). The difference might
be due to the cell lines used for the experiments. Activation of
JAK-3 by LMP-1 might be due to the particular cell line used
(Higuchi et al., 2002).
Although STATs are mostly in their latent form in EBV latency, these STATs may also have functional roles. A wellstudied example is the ability of latent STAT-1 to regulate osteoblast differentiation by attenuating Runx2, an essential
transcriptional factor in this differentiation process, in the cytoplasm (Kim et al., 2003). Another example is low-molecular weight protein 2 (LMP-2) that is involved in MHC class
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1 processing. Latent nonphosphorylated STAT-1 is able to
move into the nucleus, bind to DNA, and is responsible for
the constitutive expression of LMP-2 (Chatterjee-Kishore et
al., 2000). Also, LMP-1 has been reported to activate a STATresponsive element (Fielding et al., 2001; Richardson et al.,
2003); the induction of STAT-1, -2, and -3 could possibly explain that observation (Figure 4).
In addition, high expression levels of STATs might be related to the regulation of the EBV BamHI Q latency promoter
(Qp) which is used for the transcription of EBNA-1 in type
I latency. Activation of the JAK-STAT pathway has been reported to activate EBV Qp (Chen et al., 1999; Chen et al.,
2003). Because Qp is completely inactive in type III latency,
and STAT-1, -2, -3, and -5A are highly expressed in type III
latency, it is unlikely that any of these STATs function to activate the promoter. Also LMP-1, which is expressed in type III
latency, represses the activity of Qp reporter constructs as well
as endogenous Qp activity (Zhang and Pagano, 2000; Zhang
and Pagano, 2001; Zhang et al., 2001). Therefore, STAT-1,
-2, -3, and -5A are likely to be repressors of Qp in type III
latency. In addition, these STATs are not activated in type I
latency in which Qp is active (data not shown). These observations led us to test the role of STATs in the regulation of
Qp. However, STAT-1, -2, and -3, at least in their nonphosphorylated state, neither activate nor significantly repress Qp
in Akata cells (data not shown). It is possible that the activation of Qp by STATs might only be observable in NPC cells
(Chen et al., 2003). Thus, our data and published reports suggest that the induced but still latent STATs might be mediators
that regulate both cellular and EBV genes to the benefit of viral latency. However, the specific targets of these latent STATs
are currently unknown.
One of the chief functions of activated STATs is their involvement in the pathogenesis of human cancers. In normal
cells and in animals, ligand-dependent activation of the STATs
is a transient process, lasting for several minutes to several
hours. In contrast, in many cancerous cell lines and tumors,
where growth-factor dysregulation is frequent, STAT proteins,
especially STAT-1, -3, and -5, are persistently tyrosine-phosphorylated or activated. These activated STAT proteins play a
pivotal role in initiation and maintenance of the phenotypes of
some cancers (for a review, see Bowman et al., 2000; Bromberg and Darnell, 2000). We have shown in this report that expression of STAT-1 is associated with the EBV-transformation
process; however, STAT-2, -3, and -5A are not apparently associated with immortalization of lymphocytes into cell lines
(Figure 8). It is also reported that Bcl-2, another LMP-1-inducible gene, is not associated with the EBV transformation
(Henderson et al., 1991; Martin et al., 1993). Thus, it is apparent that not all LMP-1-inducible genes are associated with
EBV transformation. We suggest that induction of STATs, especially STAT-1, by LMP-1 may be a part of the EBV programming that regulates viral latency and leads to cellular
transformation. The overexpression of STAT-1 in EBV transformation may provide a unique scenario that differs from
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other cancers in which the tyrosine-phosphorylated STATs
are major factors in oncogenesis. The function of STAT-1 in
EBV transformation is currently under investigation. Also interesting is that type III latency cells express high levels of
two interferon regulatory factors (IRF-2 and IRF-7) (Zhang
and Pagano, 1997; Zhang and Pagano, 1999). It is well known
that IRFs are involved in the regulation of IFN responsiveness (Nguyen et al., 1997; Pitha et al., 1998; Taniguchi et al.,
2001). Thus, it is likely that EBV regulates its latency state by
the use of two families of proteins involved in the IFN signaling pathway.
In summary, our results expand the role of LMP-1 as a
pleiotropic molecule in effecting deregulation of cellular
genes. LMP-1 is now presented as a stimulator of STAT-1, -2,
and -3 in EBV-infected cells, and NF-κB is an essential factor for this induction. In addition, the expression of STAT-1 is
associated with immortalization and transformation of human
lymphocytes and lymphoblastoid cell lines.
Materials and methods
Cells, plasmids, and antibodies
DG75 is an EBV-negative Burkitt’s lymphoma (BL) cell
line (Ben-Bassat et al., 1977). Akata, Eli-BL, Rael, Sav I,
Sav III, P3HR-1, Jijoye, and Raji are all EBV-positive BL
lines (Adldinger et al., 1985; Calender et al., 1987; Klein et
al., 1972; Ragona et al., 1980; Rooney et al., 1986; Takada,
1984). LCC-1 (gift of Dr. Richard Longnecker) and CBC/
B95-8 are EBV-transformed lymphoblastoid cell lines (LCL)
(Pagano et al., 1992). BL41-P3HR1 and BL41-B95-8 are cell
lines converted by infection of EBV-negative BL41 BL cells
with the two different EBV strains (Calender et al., 1987).
Four newly transformed LCLs (LCL-1, -2, -3, and -4) are gifts
from Dr. Kenneth Izumi at the University of Texas at San Antonio. All cells were maintained in RPMI-1640 plus 10% FBS.
The fresh blood was purchased from local Red Cross station.
The CD19-positive primary B cells were isolated from fresh
PBMC by the use of CD-19 antibody conjugated to magnetic
beads according to the manufacturer’s recommendation (Dynal, Inc.). The method was used successfully, and the cells
isolated were infectable by EBV (Sinclair et al., 1994; Sinclair et al., 1995).
pcDNA/CD4, pcLMP1, the mutant LMP-1 plasmids
(LMP-PQAA, LMP-IID, and LMP-DM), EBNA-2 expression
plasmid, and NF-κB reporter constructs were all described before (Sung et al., 1991; Zhang and Pagano, 1997; Zhang and
Pagano, 2000; Zhang and Pagano, 2001; Zhang et al., 2001).
STAT-1 and STAT-3 expression plasmids were gifts from Dr.
James Darnell and Dr. Rolf de Groot, respectively. STAT-2
cDNA was from Dr. James Darnell, and the expression plasmid was constructed in pcDNA-3 vector at KpnI and XbaI
sites. Dominant-negative mutants (DN) for TRAFs (TRAF1DN, TRAF-2DN, TRAF-3DN, and TRAF-5DN ), AP-1DN,
and janus kinase 3 (JAK3) DN were described previously
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(Zhang et al., 2001). The pQ-luc reporter construct has been
described (Davenport and Pagano, 1999).
LMP-1 monoclonal antibody (CS1-4) and EBNA2 specific
antibody (PE2) were purchased from Dako. STAT-1 (sc-417,
sc-591), STAT-2 (sc-1668), STAT-3 (sc-482), and STAT-5A
(sc-1081) antibodies were purchased from Santa Cruz. Phospho-STAT-3-specific (Tyr-705; #9131) and phospho-STAT-5specific (#9351) antibodies were from Cell Signaling Technology. Phospho-Ser-727 STAT-1 antibody (#06-802) and
Phospho-Tyr-701 STAT-1 antibody (06-657) were from Upstate Biotechnology. Tubulin antibody was from Sigma. ISG15 antibody was the gift of Dr. Ernest Borden. Interferon α
(IFN-α) was from Hoffmann La Roche.
Western blot analysis with enhanced chemiluminescence
(ECL)
Separation of proteins on SDS-PAGE followed standard
methods. After the proteins were transferred to a nitrocellulose
or Immobilon membrane, the membrane was blocked with 5%
non-fat dry milk in TBST (50 mM Tris pH 7.5, 200 mM NaCl,
0.05% Tween-20) at room temperature for 10 min. It was then
washed briefly with water and incubated with a primary antibody in 5% milk in TBST for 1–2 h at room temperature, or
overnight at 4 °C. After washing with TBST for 10 min three
times, the membrane was incubated with the secondary antibody at room temperature for 1 h. It was then washed three
times with TBST as before, treated with ECL (Amersham) or
SuperSignal (Pierce) detection reagents, and exposed to Kodak XAR-5 film.
Transient transfection, chloramphenicol acetyltransferase
(CAT) assays, and isolation of transfected cells
107 cells in 0.5 ml medium were used for transfection with
the use of a BioRad Gene Pulser (320 Volts and 925 μF). Two
days after transfection, cells were collected for reporter assay or for isolation of transfected cells. The luciferase and βgalactosidase assays were essentially the same as described
(Zhang et al., 2001).
For isolation of transfected cells, enrichment for CD-4-positive cells was performed with the use of anti-CD-4-antibody
conjugated to magnetic beads according to the manufacturer’s recommendation (Dynal) as described before (Zhang and
Pagano, 1999; Zhang and Pagano, 2000; Zhang and Pagano,
2001; Zhang et al., 2001). The isolated cells were used for the
extraction of total RNA with the use of RNase Total RNA Isolation Kit (Qiagen) or for Western blot analysis.
RNA extraction and RNase Protection Assays (RPA)
RPA was performed with total RNA with the use of the
RNase Protection Kit II (Ambion, Inc.). The hybridization
temperature was 42 °C. The human STAT probe set was purchased from Pharmingen (hSTAT Multi-Probe Template Set,
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cat# 558834). The probes were generated with the use of T7
RNA polymerase. RPA autoradiography was analyzed with
the Syngene Gene Genius Bioimaging System.
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